Insilico Medicine IPO signals that AI‑native drug discovery is moving from promise to public markets with a central longevity narrative.
Insilico Medicine (3696.HK) has successfully listed on the Hong Kong Stock Exchange today, becoming the first AI-driven biotech company to go public on the Main Board under HKEX Chapter 8.05 listing rules. This initial public offering (IPO) raised a total of HK$2.277b ($293m), marking the largest biotech IPO in Hong Kong this year by funds raised [1].
“With this massively oversubscribed listing we set several world firsts, further confirming Insilico’s validated leadership position in AI-powered drug discovery and development and the strength of our platform and pipeline,” said Alex Zhavoronkov, PhD, Founder, CEO and Chief Business Officer of Insilico Medicine.
“We have validated the end-to-end capabilities of AI-empowered programs from novel target discovery to molecular generation, and then to preclinical and clinical stages. Going forward, we will continue to increase investment in our AI platform and innovative pipeline, accelerate the advancement of differentiated innovative programs into clinic, and bring truly accessible, affordable, and breakthrough treatment solutions to patients worldwide [1].”
Insilico’s Hong Kong listing, jointly sponsored by Morgan Stanley, CICC and GF Securities, attracted strong interest and active participation from both local and international investors. A total of 94,690,500 shares were offered globally, with a 10% Hong Kong public offering, which was oversubscribed by 1427 times, locking in subscription funds of more than HK$328bn and setting a record for Hong Kong public offering subscription amounts (among non‑18A healthcare IPOs) in Hong Kong during the year. The international offering accounted for 90% of the total, and was oversubscribed 26 times.
Insilico has lined up 15 cornerstone investors – including Lilly, Tencent, Temasek, Schroders and UBS Asset Management – forming an all-star line-up across pharma, tech, sovereign capital, global asset managers, and leading Chinese insurers and mutual funds.
According to Yahoo Finance, Insilico shares rose 45.5% to HK$35 in their trading debut, from their offer price of HK$24.05 [2].
Our conversations with Big Pharma execs suggest a clear thaw in the biotech winter, and Insilico’s performance could be an early signal for longevity biotech heading into 2026, despite a volatile macro backdrop.
[1] https://insilico.com/news/p010170up1-insilico-medicine-lists-on-hong-kong-sto
[2] https://uk.finance.yahoo.com/news/insilico-medicine-leads-6-hong-093000864.html
